ML
MLLNF.US Malin Corporation plc
- Market cap
- USD 32.5M
- P/E
- -
- P/B
- 0.15x
- ROE
- 0.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is MLLNF.US undervalued?
Graham numberThe Graham number of Malin Corporation plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Malin Corporation plc fundamental analysis
No fundamental analysis for Malin Corporation plc yet.
Malin Corporation plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Malin Corporation plc
Malin Corporation plc, together with its subsidiaries, operates as an investment company in Europe and North America. It engages in the investment in life sciences and healthcare companies targeting various therapeutic areas, including oncology, immunology, and genetic diseases. The company was incorporated in 2014 and is headquartered in Dublin, Ireland.
Full company profileMalin Corporation plc financial statements
Malin Corporation plc annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 21.1M | 42.1M | 41.9M | 38.0M | - | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.32M | 11.5M | 11.1M | 4.10M | - | - | - | - | - | - |
| Operating Income | -24.9M | -46.5M | -45.3M | -22.5M | - | - | -1.70M | -700K | -3.90M | -2.50M |
| EBITDA | - | - | - | - | - | - | 1.50M | 12.8M | 400K | 300K |
| Net Income | -41.4M | -83.5M | -98.8M | -46.3M | - | - | 37.8M | 12.9M | 0.00 | 0.00 |
| EPS | - | - | - | - | - | - | 1.01 | 0.37 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 424M | 403M | 308M | 264M | - | - | 228M | 288M | 117M | 199M |
| Total Liabilities | 58.8M | 94.8M | 86.6M | 94.0M | - | - | 9.30M | 4.80M | 7.10M | 5.30M |
| Shareholders' Equity | 365M | 308M | 221M | 170M | - | - | 219M | 283M | 110M | 193M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 32.7M | 174M | 29.3M | 62.1M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -15.7M | -22.4M | -27.2M | -13.4M | -4.10M | -3.00M | -4.60M | -7.20M | -3.20M | -1.30M |
| Capital Expenditure | 369K | 1.00M | 1.20M | 1.60M | 1.00M | 400K | 800K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | - | - | - | -6.20M | -7.20M | -3.20M | -1.30M |
| Ratios | ||||||||||
| ROE | -11.3% | -27.1% | -44.6% | -27.2% | - | - | 17.3% | 4.6% | 0.0% | 0.0% |
| ROA | -9.8% | -20.7% | -32.1% | -17.5% | - | - | 16.6% | 4.5% | 0.0% | 0.0% |
| Net Profit Margin | -196.1% | -198.3% | -235.8% | -121.8% | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Malin Corporation plc dividends
Malin Corporation plc has not paid dividends in the last 10 fiscal years.
Who owns Malin Corporation plc
- Insiders 34.96%
- Institutions 44.29%
- Public & others 20.75%
- Shares outstanding 4.33M
- Free float 893K
Malin Corporation plc company profile
- Company name
- Malin Corporation plc
- Ticker
- MLLNF.US
- ISIN
- IE00BVGC3741
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 2
- Fiscal year end
- December
- Address
- The Lennox Building, Dublin, Ireland, D02 FK02
- Phone
- 353 1 905 3531
- Website
- malinplc.com
About Malin Corporation plc
Malin Corporation plc, together with its subsidiaries, operates as an investment company in Europe and North America. It engages in the investment in life sciences and healthcare companies targeting various therapeutic areas, including oncology, immunology, and genetic diseases. The company was incorporated in 2014 and is headquartered in Dublin, Ireland.
Malin Corporation plc management
2- Mr. William F. DanielExecutive Chair · born 1952
- Andrea StaffordHead of Finance & Company Secretary